Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2285 • ACR Convergence 2025
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Theresa Wampler Muskardin¹, Ruiqi Chen², Yeji Lee³, Azka Ali³, Andrra Nimoni³, Christele Felix³, Hattie Heiland³, Romy Kallas³, Daniel Ramirez⁴, David Mayman³, Timothy Niewold⁵ and Weiqiang Chen⁶, ¹Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, ²New York University - Tandon School of Engineering, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, New York, ⁶New York University, Tandon School of Engineering, New York, NY
Background/Purpose: In rheumatoid arthritis (RA), reasons for treatment resistance and alternate strategies that would be more effective in treatment-resistant patients remain unknown. Accurate methodology to…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…
Abstract Number: 2235 • ACR Convergence 2025
Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
Erica Mulcaire-Jones¹, Suiyuan Huang¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Grace Qian⁵, Liya Sisay Getachew⁶, Emily Kowalski⁶, Kevin Mueller⁵, Alene Saavedra⁵, Lauren O'Keeffe⁵, Natalie Davis⁷, Alison Puri⁸, Kathleen Vanni⁵, Caleb Bolden⁹, Tina Mahajan¹⁰, Marzieh Jamali¹, Pierre Antoine Juge¹¹, Tracy J. Doyle¹², Marcy Bolster¹³, Kevin Deane¹⁴, Raul San Jose Estepar⁵, George Washko⁵, Gregory McDermott⁷, Bryant England¹⁰, Jeffrey Sparks⁶ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Boston University, Brookline, MA, ⁹Massachusetts General Hospital, Boston, ¹⁰University of Nebraska Medical Center, Omaha, NE, ¹¹Hopital Bichat, APHP, Paris, France, ¹²Brigham and Women's Hospital, West Roxbury, MA, ¹³Massachusetts General Hospital, Concord, MA, ¹⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Several lung diseases are associated with rheumatoid arthritis (RA), including interstitial lung disease (ILD) and emphysema. In RA-ILD baseline lung function and decline in…
Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1927 • ACR Convergence 2025
Development of the PREVAIL model of care: Optimizing feasibility and acceptability for trial implementation
Louise Thoma¹, Joel Thompson², Jason Sharpe³, Beth Jonas⁴, Patti Katz⁵ and Kelli Allen⁶, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Cary, NC, ³Flatiron Health, Durham, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵UCSF, San Rafael, CA, ⁶University of North Carolina, Durham, NC
Background/Purpose: Exercise guidance and referral to physical therapy are not consistently delivered when appropriate in rheumatology care for adults with rheumatoid arthritis (RA). The PREVAIL…
Abstract Number: 1749 • ACR Convergence 2025
External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis
Mikael Brink¹, Austin Wheeler², Bryant England² and Solbritt Rantapaa-Dahlqvist³, ¹Umeå Universitet, Umeå, Sweden, ²University of Nebraska Medical Center, Omaha, NE, ³Umeå University, Umea, Sweden
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) causes substantial morbidity and mortality in RA. Despite this, a limited number of clinical and genetic risk factors have…
Abstract Number: 1676 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
Roy Fleischmann¹, Jerzy Swierkot², Patrick Durez³, Louis Bessette⁴, Xianwei Bu⁵, Irina Fish⁵, Andrew Gara⁵, Diane Caballero⁵, Charles Peterfy, MD, PhD⁶, Yoshiya Tanaka⁷ and Eduardo Mysler⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Wroclaw Medical University, Department of Rheumatology and Internal Medicine, Wroclaw, Poland, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁵AbbVie Inc., North Chicago, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: We assessed the safety and efficacy of UPA versus ADA from SELECT-COMPARE through 7-years.Methods: Patients with RA and an inadequate response to MTX were…
Abstract Number: 1372 • ACR Convergence 2025
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…
Abstract Number: 1354 • ACR Convergence 2025
Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Hongtao Jin, Huifang Guo, Yuxiang Han and Meng Ding, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic)
Background/Purpose: Joint swelling and tenderness are major symptoms of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of ivarmacitinib (SHR0302), a selective Janus kinase…
Abstract Number: 1337 • ACR Convergence 2025
The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
Ariel Israel¹, Fadi Hassan², Jalal Kurtam², Jamal Awad², Eugene Merzon¹ and Mohammad Naffaa³, ¹Leumit Health Services, Tel-Aviv, Israel, ²Galilee Medical Center, Nahariya, Israel, ³The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel
Background/Purpose: The increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) for diabetes mellitus (DM) and weight loss has the potential modify the risk for rheumatoid…
Abstract Number: 1321 • ACR Convergence 2025
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
Olga Compán¹, Marta Ibañez², Olga Martínez³, Carolina Cristina Chacón⁴, Ricardo López Pérez³, Borja Felices López³, Belén Miguel Ibáñez³, Laura Blanco⁴, Sergio Cimadevila Santiago³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martin Martinez³, Cristina Hidalgo Calleja⁴, Carlos Montilla⁴ and Susana Gómez⁴, ¹Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain, ²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ³Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].